Resources for Food and Drug Administration (FDA)

BioMarin reports receipt of FDA approval for Kuvan for PKU

www.tradingmarkets.com

BioMarin Pharmaceutical, a provider of biopharmaceuticals for serious diseases and medical conditions, declared on 13 December that the company has received marketing approval for Kuvan (sapropterin dihydrochloride) Tablets, the first specific drug therapy approved for the treatment of phenylketonuria (PKU), from the US Food and Drug Administration (FDA).

View the Resource

Share or bookmarklet this web page at: